EQL Pharma AB (publ) reported earnings results for the fourth quarter and full year ended March 31, 2022. For the fourth quarter, the company reported sales was SEK 203.03 million compared to SEK 25.81 million a year ago. Net income was SEK 6.51 million compared to net loss of SEK 6.24 million a year ago. Basic earnings per share from continuing operations was SEK 0.22 compared to basic loss per share from continuing operations of SEK 0.21 a year ago.
For the full year, sales was SEK 409.75 million compared to SEK 179.14 million a year ago. Net income was SEK 31.55 million compared to SEK 10.37 million a year ago. Basic earnings per share from continuing operations was SEK 1.09 compared to SEK 0.36 a year ago.